Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. It also provides raw material products, including … Read more
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Total Liabilities
Latest total liabilities as of September 2025: CN¥142.19 Million CNY
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has total liabilities worth CN¥142.19 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Total Liabilities Trend (2017–2024)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baotou Dongbao Bio-Tech Co Ltd
SHE:300239
|
China | CN¥851.75 Million |
|
Gedik Yatirim Menkul Degerler AS
IS:GEDIK
|
Turkey | TL15.30 Billion |
|
Whirlpool of India Limited
NSE:WHIRLPOOL
|
India | ₹23.97 Billion |
|
Danal Co. Ltd
KQ:064260
|
Korea | ₩519.07 Billion |
|
Cinda Real Estate Co Ltd
SHG:600657
|
China | CN¥53.30 Billion |
|
Holtek Semiconductor Inc
TW:6202
|
Taiwan | NT$1.65 Billion |
|
Jiangsu Boamax Technologies Group Co Ltd
SHE:002514
|
China | CN¥1.58 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2024)
The table below shows the annual total liabilities of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥178.97 Million | -5.75% |
| 2023-12-31 | CN¥189.89 Million | -14.16% |
| 2022-12-31 | CN¥221.22 Million | +105.73% |
| 2021-12-31 | CN¥107.53 Million | +4.55% |
| 2020-12-31 | CN¥102.85 Million | -60.03% |
| 2019-12-31 | CN¥257.31 Million | +7.05% |
| 2018-12-31 | CN¥240.36 Million | +5.77% |
| 2017-12-31 | CN¥227.25 Million | -- |